BiotechTube

KK8398

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Achondroplasia

Conditions

Achondroplasia

Trial Timeline

Dec 1, 2024 → May 31, 2031

NCT ID
NCT06926491

About KK8398

KK8398 is a phase 3 stage product being developed by Kyowa Kirin for Achondroplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06926491. Target conditions include Achondroplasia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06926491Phase 3Recruiting

Competing Products

20 competing products in Achondroplasia

See all competitors
ProductCompanyStageHype Score
ReciferceptPfizerPhase 2
51
ReciferceptPfizerPhase 2
51
TransCon CNPAscendis PharmaPhase 2/3
62
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2/3
62
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2
49
Navepegritide + Placebo for NavepegritideAscendis PharmaPhase 2
49
Navepegritide + Placebo for navepegritideAscendis PharmaPhase 2
49
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2
49
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsAscendis PharmaPhase 2
49
BMN 111 + Normal SalineBioMarin PharmaceuticalPhase 1
30
BMN 111BioMarin PharmaceuticalPhase 2
49
BMN 111 + PlaceboBioMarin PharmaceuticalPhase 2
49
BMN 111 administration via vial and syringeBioMarin PharmaceuticalPhase 1
30
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.BioMarin PharmaceuticalPhase 2
49
BMN 111BioMarin PharmaceuticalPhase 2
49
BMN 111 + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN 333 + Vosoritide Injection [Voxzogo]BioMarin PharmaceuticalPhase 2/3
62
vosoritideBioMarin PharmaceuticalPhase 2
49
BMN 111BioMarin PharmaceuticalPhase 3
74
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kgTyra BiosciencesPhase 2
47

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85